Medlab Group PTY LTD was incorporate by Dr Hall, Dec 2023 and at that time acquired of Medlab IP PTY LTD and Medlab Clinical US Inc.

Whilst there are many different Medlab-named companies, the Medlab Group of Companies are not connected to any other Medlab organisations.

The former company, Medlab Clinical Limited was a public biotechnology company that was embarking on the development of new pharmaceutical products subject to various regulatory approvals such as the US FDA. The former company, Medlab Clinical Limited underwent restructure, allowing for the acquisition of the subsidarises by Dr Hall.

Out-licensing, is when a company (the licensor) grants another organization (the licensee) the rights to use its product, technology, or intellectual property. In this case, the licensor typically receives royalties, upfront fees, or milestone payments from the licensee.

Yes, we endeavour to make “partnering” as seamless and efficient as possible, read about our key elements here.

No. We don’t sell or market products, we licence technologies that an organisation like a pharmaceutical, nutraceutical, cosmetic or food company may incorporate into their range of products.

No. the former Medlab Clinical Limited, sold off the Australian rights for select nutraceuticals to a company called Pharmacare, owners of the Bioglan brand. The Pharmacare agreement pre-dates the General Meeting in Dec 2023 which created Medlab Group PTY LTD. Pharmacare has the rights to use NanoCelle in select nutraceuticals, D3 and B12 being an example, for Australia only.

As per resolutions of the Dec 2023 EGM (ASX:MDC) if you where a security holder as at the record date of 12 JAN 2024, you become a Royalty holder of Medlab Group until 12 JAN 2028. Please refer to the Dec 2023 EGM reading pack and outcomes for specifics.

Unless you had securities in ASX:MDC as at 12 Jan 2024, you can not.